Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Tuesday, April 29th. Analysts expect Regeneron Pharmaceuticals to post earnings of $8.83 per share and revenue of $3.40 billion for the quarter.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $11.86 earnings per share. On average, analysts expect Regeneron Pharmaceuticals to post $36 EPS for the current fiscal year and $38 EPS for the next fiscal year.
Regeneron Pharmaceuticals Price Performance
Shares of NASDAQ REGN traded up $2.88 during trading on Friday, hitting $602.64. 964,377 shares of the company were exchanged, compared to its average volume of 723,778. Regeneron Pharmaceuticals has a 1 year low of $525.99 and a 1 year high of $1,211.20. The company has a market cap of $65.88 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 2.34 and a beta of 0.44. The firm's fifty day moving average price is $637.38 and its 200 day moving average price is $725.82. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.
Regeneron Pharmaceuticals Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.
Wall Street Analysts Forecast Growth
REGN has been the subject of a number of research analyst reports. Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a research note on Tuesday, February 4th. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday. They issued an "overweight" rating and a $695.00 price objective for the company. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $945.32.
Read Our Latest Research Report on REGN
Institutional Inflows and Outflows
An institutional investor recently raised its position in Regeneron Pharmaceuticals stock. Brighton Jones LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 261.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 948 shares of the biopharmaceutical company's stock after purchasing an additional 686 shares during the quarter. Brighton Jones LLC's holdings in Regeneron Pharmaceuticals were worth $675,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 83.31% of the company's stock.
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Articles
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
